Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of "Buy" by Brokerages

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six brokerages that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $34.50.

Several research analysts have recently issued reports on CAPR shares. Cantor Fitzgerald restated an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a report on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th.

Capricor Therapeutics Trading Down 6.9 %

Capricor Therapeutics stock traded down $0.88 on Wednesday, reaching $11.86. 1,280,546 shares of the stock were exchanged, compared to its average volume of 1,511,130. The stock has a market cap of $541.73 million, a PE ratio of -11.19 and a beta of 0.85. The firm has a fifty day moving average price of $11.84 and a two-hundred day moving average price of $14.65. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $11.13 million during the quarter, compared to analysts' expectations of $9.87 million. Equities analysts anticipate that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds have recently modified their holdings of CAPR. Summit Investment Advisors Inc. boosted its stake in Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after buying an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter worth about $68,000. AlphaQuest LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth about $78,000. Finally, New York State Common Retirement Fund lifted its holdings in Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 5,000 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.